Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. Armstrong AJ, Halabi S, Healy P, Alumkal JJ, Winters C, Kephart J, Bitting RL, Hobbs C, Soleau CF, Beer TM, Slottke R, Mundy K, Yu EY, George DJ.. Eur J Cancer. 2017;81():228-236.
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, Robinson M, Bitting RL, Thomas A, Alistar AT, Desnoyers RJ, Goodman M, Albright C, Porosnicu M, Vatca M, Qasem SA, DeYoung B, Kytola V, Nykter M, Chen K, Levine EA, Staren ED,.. J Hematol Oncol. 2017;10(1):100.
Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution. Davis K, Wood S, Dill E, Yuri Fesko YF, Bitting RL, Harrison MR, Armstrong AJ, Moul JW, George DJ.. Clin J Oncol Nurs. 2015;19(3):297-303.
Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy [abstract]. Li J, Beaver J, Bitting RL, Gregory S, Armstrong AJ.. J Clin Oncol. 2015;33(15 Suppl):5042.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.
Assistant Professor, Hematology & Oncology
Genitourinary Cancer, Bladder Cancer, Prostate Cancer, Genitourinary Oncology
The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.
Only went there one time, got to go back.
Dr. Bitting along with a NP seem to have all the bases covered. I checked their online notes and found that I was quoted with total accuracy. They were not typing like crazy but looked at me and listened, and I listened to them. They were not obsessed with entering data into the computer. They did it later. High marks for the NP and Dr Bitting.
I have nothing but high regards for Dr. Rhonda Bitting.
Doctor Bitting is the best in all aspects
*Dr. Bitting was most courteous and pleasant. I felt her knowledge and professionalism were excellent. She is a great asset to Baptist Health - W.J.
I came into this appointment with a lot of apprehension but Dr Bitting helped assure me with her personable and positive approach. She won me over as did the NP.
I am very glad that Dr Bitting is my care provider. She and her assistant Toni have been there for me through my cancer treatment!. I am very thankful to them!
We begin a journey w/*Dr. Bitting much respect & confidence in her.
I tell my testimony to all I meet - That Wake Cancer Center and *Dr. Bitting are the most caring and best cancer center around. Thanks to God, *Dr. Bitting and Wake for saving my life and extending an excellent quality of life. *Dr. Bitting goes that extra step for me!
I recommend your hospital many times.
My experience with Dr Bitting and all of the Wake Forrest Baptist Hospital staff has always been the greatest. I travel over a thousand miles one way just to access this wonderful service.
Talking with *Dr. Bitting is reassuring even when the results are very negative health issues.
in this field of medical oncology, secure and confident rapport is vital. Dr. Bitting provides both. In malignancy, the attitude of caregiver is almost as vital as medications and surgical care; she gives confidence. In this field of depressive outlook, she gives you a strong, positive outlook with optimism that is realistic.
I am a new patient. I am very pleased with my experience. Also grateful for your being available.